



N30 Pharmaceuticals Fact Sheet



August 1, 2010 Vol. VIII

The leader in developing new s-nitrosothiol (SNO)-based drugs

N30's drugs target is S-nitrosoglutathione reductase (GSNOR), an enzyme of central importance in human health and disease.




N30 drugs inhibit GSNOR, the most selective enzyme that breaks down S-nitrosoglutathione (GSNO), a key component of the human body's pool of bioavailable nitric oxide. GSNO and SNOs are important modulators of inflammation, cell death, and respiratory, vascular, and gastrointestinal function. Inhibition of GSNOR increases the levels of endogenous, bioreactive nitric oxide. Modulating GSNOR enzymatic activity is an important new therapeutic strategy for the treatment of major diseases such as asthma, COPD, inflammatory bowel disease, and vascular disease.

Highlights of N30 Development:

N30 has developed a platform of chemistry, biology, advanced analytic techniques, and state-of-the-art clinical testing. This has resulted in a broad portfolio of high potency (nM) compounds within multiple chemotypes. N30 drug candidates have demonstrated efficacy in a broad range of human

disease models. These drugs are notable in their broad anti-inflammatory activity, effect on smooth muscle, duration of effect, safety profile, and varying methods of administration, including I.V., oral, and inhalation. These drugs are protected by a patent portfolio built upon compositional claims. N30's first drug candidate N6022, initially targeting respiratory disease, is now entering human testing.

N30 GSNOR Inhibitors Inflammation and Airspace Enlargement in Experimental COPD



N30 GSNOR Inhibitors Preserve GI Integrity In Experimental Inflammatory Bowel Disease



Executive Management

Charles Scoggin MD: Chief Executive officer

Gary Rosenthal PhD: Executive Vice President Research

Janice Troha: VP Development and Regulatory

Tom Sokolowski: CFO and VP Finance

Scientific Advisors

Joseph Loscalzo MD PhD: Harvard Medical School

Augustin Choi MD: Harvard Medical School

Michael Marletta PhD: University of California, Berkeley

Joseph Vita MD; Boston University

William Sessa PhD: Yale

Jan Wasley PhD: Simpharma

Gordon Letts PhD: TargAnox

Board of Directors

Arnold Snider: Chairman

Joseph Loscalzo: Harvard Medical School

Howard Furst MD: Deerfield Management

Michael Treisman: Tiger Management

Charles Scoggin MD: CEO N30

Investors

Tiger Management

Deerfield Management

Arnold Snider

Bridger Capital

Swift Current Partners

Duke University

N30 Pharmaceuticals

3122 Sterling Circle, Suite 200
Boulder, Colorado 80301

720.945.7700

303.440.8399

www.n30pharma.com